Judy M2 Posted April 7, 2021 Share Posted April 7, 2021 This article was posted by a member of the LUNGevity EGFR Resisters Lung Cancer Patients Group. Not only is neratinib being tested as a targeted therapy for EGFR Exon 18 mutations but also HER and HER2 tumor mutations and for other cancers. Go science! https://www.targetedonc.com/view/neratinib-is-effective-against-egfr-exon-18-mutations-in-nsclc Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.